TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 76.1M
Total Liabilities 28.1M
Shareholders Equity 48.1M
Debt to Equity 0.58

Cash Flow Metrics

Revenue & Profitability Trend

Onward Medical N.V Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i229.0K68.0K000
Cost of Goods Sold i22.0K014.7M12.0M2.3M
Gross Profit i207.0K68.0K-14.7M-12.0M-2.3M
Gross Margin % i90.4%100.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i12.4M13.8M13.1M7.9M5.8M
Selling, General & Administrative i5.7M6.3M6.5M7.8M3.0M
Other Operating Expenses i3.5M2.8M3.9M993.0K361.0K
Total Operating Expenses i21.6M23.0M23.5M16.7M9.2M
Operating Income i-34.9M-35.5M-32.0M-28.5M-15.5M
Operating Margin % i-15,223.6%-52,151.5%0.0%0.0%0.0%
Non-Operating Items
Interest Income i791.0K972.0K62.0K1.0K0
Interest Expense i2.0M1.4M1.5M5.6M4.4M
Other Non-Operating Income-----
Pre-tax Income i-35.8M-36.1M-33.5M-34.2M-20.0M
Income Tax i-40.0K107.0K-766.0K69.0K20.0K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-35.7M-36.2M-32.8M-34.3M-20.0M
Net Margin % i-15,600.4%-53,207.4%0.0%0.0%0.0%
Key Metrics
EBITDA i-32.9M-34.0M-31.3M-28.3M-15.3M
EPS (Basic) i€-0.80€-1.20€-1.09€-3.62€-3.39
EPS (Diluted) i€-0.80€-1.20€-1.09€-3.62€-3.39
Basic Shares Outstanding i44629000301840003018400094850005900000
Diluted Shares Outstanding i44629000301840003018400094850005900000

Income Statement Trend

Onward Medical N.V Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i60.0M29.8M41.8M89.4M6.4M
Short-term Investments i--20.0M--
Accounts Receivable i160.0K0---
Inventory i102.0K0---
Other Current Assets-305.0K285.0K2.2M416.0K
Total Current Assets i63.6M31.4M64.2M92.4M7.0M
Non-Current Assets
Property, Plant & Equipment i0002.2M149.0K
Goodwill i12.4M11.6M12.1M11.7M8.4M
Intangible Assets i8.5M8.0M8.3M8.3M5.2M
Long-term Investments-----
Other Non-Current Assets-1.0K----
Total Non-Current Assets i12.5M12.2M12.4M12.4M7.2M
Total Assets i76.1M43.6M76.6M104.8M14.2M
Liabilities
Current Liabilities
Accounts Payable i1.3M1.4M1.9M952.0K911.0K
Short-term Debt i597.0K568.0K427.0K473.0K137.0K
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i9.3M6.7M8.2M5.5M2.7M
Non-Current Liabilities
Long-term Debt i14.5M16.3M14.0M13.2M41.9M
Deferred Tax Liabilities i303.0K631.0K670.0K2.0M1.3M
Other Non-Current Liabilities---1.0K-
Total Non-Current Liabilities i18.8M19.0M15.7M16.6M43.6M
Total Liabilities i28.1M25.7M24.0M22.1M46.3M
Equity
Common Stock i5.4M3.6M3.6M3.6M0
Retained Earnings i-181.8M-145.4M-108.3M-76.0M-53.1M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i48.1M17.9M52.6M82.7M-32.1M
Key Metrics
Total Debt i15.1M16.9M14.4M13.7M42.0M
Working Capital i54.3M24.7M56.0M86.8M4.3M

Balance Sheet Composition

Onward Medical N.V Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-35.8M-36.1M-33.5M-34.2M-20.0M
Depreciation & Amortization i-----
Stock-Based Compensation i2.7M2.6M1.7M8.6M2.7M
Working Capital Changes i-1.9M491.0K140.0K-2.4M-221.0K
Operating Cash Flow i-33.9M-32.2M-30.1M-22.3M-13.0M
Investing Activities
Capital Expenditures i-150.0K-422.0K-386.0K-91.0K-173.0K
Acquisitions i-----
Investment Purchases i00-20.0M0-
Investment Sales i020.0M0--
Investing Cash Flow i-150.0K19.6M-20.4M-91.0K-173.0K
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i14.1M1.3M030.0M3.9M
Debt Repayment i-15.3M0---
Financing Cash Flow i68.9M1.3M0110.1M4.5M
Free Cash Flow i-31.9M-32.7M-27.1M-22.2M-13.1M
Net Change in Cash i34.9M-11.3M-50.5M87.7M-8.7M

Cash Flow Trend

Onward Medical N.V Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -6.48
Forward P/E -4.65
Price to Book 8.34
Price to Sales 85.17

Profitability Ratios

Profit Margin 90.39%
Operating Margin -1,685.49%
Return on Equity -167.80%
Return on Assets -43.66%

Financial Health

Current Ratio 4.34
Debt to Equity 54.33
Beta 0.95

Per Share Data

EPS (TTM) €-0.74
Book Value per Share €0.62
Revenue per Share €0.06

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
onwd245.2M-6.488.34-167.80%90.39%54.33
Argenx SE 38.4B37.826.3324.72%41.03%0.71
UCB S.A 39.1B29.724.0014.30%19.45%29.72
Hyloris 169.7M-5.24-17.81%-64.98%5.65
European Medical 21.8M44.152.355.40%1.14%191.98
Celyad Oncology S.A 13.4M-0.1725.00-170.92%0.00%177.10

Financial data is updated regularly. All figures are in the company's reporting currency.